BiomX Inc.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Gaithersburg, MD.

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today a corporate restructuring plan to focus its resources and extend the cash runway. The Company had $55.7 million in cash, cash equivalents and short-term deposits and a $15 million debt facility as of March 31, 2022. Due to the current

BiomX Announces Corporate Restructuring

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper titled “Exodus: Sequencing-based Pipeline for Quantification of Pooled Variants” in the journal, Bioinformatics. The research was conducted by scientists at BiomX and is available online at https:

BiomX Announces Publication in the Journal, Bioinformatics

BiomX Inc. (NYSE:PHGE ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Operator Good morning. And welcome to BiomX First Quarter 2022 Financial Results and Corporate Update Conference Call.

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q1 2022 Results - Earnings Call Transcript

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the first quarter ended March 31, 2022. “We are continuing to make progress with our pipeline. In our cystic fibrosis (“CF”) program, we are working actively to enroll patients in o

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a virtual key opinion leader (“KOL”) webinar on BX004 for the treatment of Pseudomonas Aeruginosa (“PsA”) infections in patients with cystic fibrosis (“CF”) on Thursday, May 12, 2022 at 11:00 a.m. EDT. BiomX

BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, May 11, 2022, at 8:00 a.m. EDT, to report first quarter 2022 financial results and provide business updates. To participate in the conference call, pl

BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q4 2021 Results - Earnings Call Transcript

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the fourth quarter and full year ended December 31, 2021. “BiomX is now entering the most exciting period in its history, with proof-of-concept clinical data readouts expected in th

BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, March 30th, 2022, at 8:00 a.m. EDT, to report fourth quarter and full year 2021 financial results and provide business updates. To participate in the conference call, p

BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Presenting at Three Upcoming Investor Conferences

BiomX Presenting at Three Upcoming Investor Conferences

BRANFORD, Conn. & NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will receive a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation (“CF Foundation”). “We are very pleased to receive the support of the Cystic Fibrosis Foundation – an organization

BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation

Jefferies London Healthcare Conference on November 18 - 19, 2021

BiomX Presenting at Two Upcoming Conferences in November

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q3 2021 Results - Earnings Call Transcript

Announces Strategic Focus on Cystic Fibrosis and Atopic Dermatitis Programs Based on Potential Proof-of-Concept Clinical Data Readouts in 2022

BiomX Reports Third Quarter 2021 Financial Results and Provides Business Update

BiomX Inc. (PHGE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 28.1% in 4 Weeks, Here's Why BiomX Inc. (PHGE) Looks Ripe for a Turnaround

BiomX Inc (NYSE: PHGE) announced results from its Phase 2 study to assess BX001 to improve the appearance of skin in acne-prone subjects.  A statistically significant improvement from baseline was observed in the appearance of acne-prone skin, but no meaningful difference was demonstrated relative to the vehicle.

BiomX's Acne Vulgaris Treatment Fails To Top Vehicle Treatment Cohort

The stock price of BiomX Inc (NYSEAMERICAN: PHGE) fell by over 5% pre-market today. This is why it happened.

PHGE Stock: Why The Price Fell Today

12-Week Study of BX001 Meets Safety and Tolerability Endpoints

BiomX Reports Topline Results of Phase 2 Cosmetic Acne Study

BiomX Inc. (NYSE: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license BiomX's atopic dermatitis product candidate, BX005, in Japan.

BiomX Enters Agreement Granting Maruho Co. A right Of First Offer To License BiomX's Atopic Dermatitis Product Candidate BX005; Maruho Will Also Enter Binding Agreement For $3M Equity Investment In BiomX

BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. Ltd., a leading dermatology-focused pharmaceutical company in Japan, a right of first offer to license BiomX's atopic dermatitis product candidate, BX005, in Japan. The right of first offer will commence following the availability of results from the Phase 1/2 study of BX005 expected in 2022. Maruho also entered into a binding agreement for an equity investment in BiomX of $3 million at a premium to the market share price, intended primarily to support the Phase 1/2 study.

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

Utilizing its proprietary BOLT and synthetic biology platforms, BiomX develops natural and engineered phage therapeutic cocktails to treat chronic diseases ranging from acne, IBD, PSC, CF, A. Dermatitis and colorectal cancer. BiomX currently has four Phase 2 clinical trial readouts during the next 8 months including a Phase 2 acne trial readout late this month.

BiomX: Undervalued With Multiple Upcoming Catalysts

BiomX, Inc. designs species-specific phage cocktails to neutralize bacteria prevalent in many disease types.

BiomX: An Intriguing Name That Should Be On Your Watchlist

BRANFORD, Conn. and NESS ZIONA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced Jonathan Solomon, Chief Executive Officer, will be presenting at three upcoming virtual investor events in September.

BiomX to Present at Upcoming September Investor Conferences

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2021 Results - Earnings Call Transcript

Up to $45 Million Secured from Recent Capital Raises Extends Cash Runway to at Least Mid-2023

News for BiomX Inc. Stock (PHGE)